4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Frequently asked questions
What sector does 4D Molecular Therapeutics Inc (FDMT) operate in?
4D Molecular Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is 4D Molecular Therapeutics Inc (FDMT) current stock price?
As of the latest data, 4D Molecular Therapeutics Inc stock price is $14.72, with a previous close of $14.55. 4D Molecular Therapeutics Inc gained $0.18 in the last trading session, representing a 1.2% increase.
What is 4D Molecular Therapeutics Inc (FDMT) current market capitalization?
4D Molecular Therapeutics Inc market cap is approximately 769.51 million.
What is 4D Molecular Therapeutics Inc (FDMT) Earnings Per Share (EPS)?
The trailing EPS is -$2.65, and the forward EPS is -$3.83.
What is 4D Molecular Therapeutics Inc (FDMT) EBITDA?
4D Molecular Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -66.70 million.
Does 4D Molecular Therapeutics Inc (FDMT) pay dividends?
No. 4D Molecular Therapeutics Inc does not pay a dividend.
How did 4D Molecular Therapeutics Inc (FDMT) perform in its most recent earnings report?
In the last report (June 30, 2026), 4D Molecular Therapeutics Inc posted an EPS surprise of -1% and a revenue surprise of 17.76%.
What is 4D Molecular Therapeutics Inc (FDMT) beta (volatility) score?
4D Molecular Therapeutics Inc has a beta of 2.690, indicating very high volatility compared to the market.
